2022
Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients?
Khoury J, Ghersin I, Braun E, Elias A, Aronson D, Azzam Z, Bahouth F. Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients? Israel Medical Association Journal 2022, 24: 757-762. PMID: 36436045.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureAngiotensin receptor blockersPatients 80 yearsEjection fractionHeart failureMedicine groupSingle-center retrospective studyDecompensated heart failureReduced ejection fractionLarge prospective studiesRandomized clinical trialsOlder adult populationGDMT groupMineralocorticoid antagonistsCause mortalityReceptor blockersValue of guidelinesElderly patientsHospital dischargeOlder patientsYounger patientsMedical therapyPrimary outcomeProspective studyRetrospective studyEffectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clinical Infectious Diseases 2022, 76: 453-460. PMID: 36130189, DOI: 10.1093/cid/ciac781.Peer-Reviewed Original ResearchConceptsSevere COVID-19Composite outcomeSevere acute respiratory syndrome coronavirus 2COVID-19-specific mortalityModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Propensity Score Matched AnalysisCOVID-19-related mortalityCOVID-19Respiratory syndrome coronavirus 2High-risk patientsTreatment of mildSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerHazard ratioVaccination statusMatched AnalysisCoronavirus 2Subgroup analysisDisease 2019High riskPositive testPatientsEffectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases 2022, 76: e342-e349. PMID: 35653428, PMCID: PMC9214014, DOI: 10.1093/cid/ciac443.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 vaccination statusVaccination statusHazard ratioCOVID-19Severe acute respiratory syndrome coronavirus 2High-risk patients trialModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Adjusted hazard ratioHigh-risk patientsTreatment of mildCox hazard regressionSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerEligible patientsOlder patientsRisk patientsHazards regressionCoronavirus 2Cardiovascular diseaseTime-dependent variables
2020
SOFA score and short-term mortality in acute decompensated heart failure
Elias A, Agbarieh R, Saliba W, Khoury J, Bahouth F, Nashashibi J, Azzam Z. SOFA score and short-term mortality in acute decompensated heart failure. Scientific Reports 2020, 10: 20802. PMID: 33257739, PMCID: PMC7705654, DOI: 10.1038/s41598-020-77967-2.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureSequential Organ Function Assessment (SOFA) scoreShort-term mortalityDecompensated heart failureSOFA scoreHigh-risk patientsHospital mortalityRisk patientsHeart failureLife-threatening conditionCurve (AUC) of receiverFirst hospitalizationPrimary diagnosisRisk scorePatientsMortalityAssessment scoresStrict monitoringExcellent scoresCharacteristic curveHospitalizationScoresGood predictive accuracyProper managementSepsis
2019
Clinical characteristics and outcomes of patients with Escherichia coli in airway samples
Schneer S, Khoury J, Adir Y, Stein N, Mishan P, Ken‐Dror S, Weber G, Meler R, Khateeb A, Shteinberg M. Clinical characteristics and outcomes of patients with Escherichia coli in airway samples. The Clinical Respiratory Journal 2019, 14: 205-213. PMID: 31799802, DOI: 10.1111/crj.13116.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsBronchiectasisCase-Control StudiesCommunity-Acquired InfectionsCross InfectionCystic FibrosisDrug Resistance, BacterialEscherichia coliEscherichia coli InfectionsFemaleHospitalizationHumansMaleMicrobial Sensitivity TestsMiddle AgedRespiratory Tract InfectionsSputumConceptsRespiratory secretionsResistant E. coliE. coli positive culturesResistant strainsMore hospitalization daysOutcomes of patientsGroup of patientsCommunity-acquired infectionsClinical characteristicsHospital daysPulmonary infectionHospitalization daysAmbulatory patientsPrevious hospitalizationAirway samplesPrognostic valueRespiratory pathogensCommon pathogensPositive culturesPatientsNosocomial pathogenAntibiotic classesAntimicrobial classesSecretionElevated mortalityExtrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. Journal Of Gastrointestinal Cancer 2019, 51: 584-590. PMID: 31407252, DOI: 10.1007/s12029-019-00293-y.Peer-Reviewed Original ResearchConceptsHepatitis C virusExtrahepatic malignanciesAntiviral agentsParitaprevir/ritonavir/ombitasvirChronic hepatitis C virusRecurrent metastatic breast cancerRecurrent transitional cell carcinomaMethodsFour hundred thirtyChronic HCV infectionDirect antiviral agentsMetastatic breast cancerTreatment of choiceTransitional cell carcinomaPossible relationshipDAA treatmentResultsNine patientsHCV infectionCommon regimenCell carcinomaC virusLaryngeal carcinomaPancreatic adenocarcinomaLung carcinomaBreast cancerUrinary bladderBlood urea nitrogen variation upon admission and at discharge in patients with heart failure
Khoury J, Bahouth F, Stabholz Y, Elias A, Mashiach T, Aronson D, Azzam Z. Blood urea nitrogen variation upon admission and at discharge in patients with heart failure. ESC Heart Failure 2019, 6: 809-816. PMID: 31199082, PMCID: PMC6676277, DOI: 10.1002/ehf2.12471.Peer-Reviewed Original ResearchConceptsBlood urea nitrogenDay mortality rateHeart failureHigher BUN levelsPrognostic predictorBUN levelsMortality rateAcute decompensated heart failureDecompensated heart failureLong-term mortalityBrain natriuretic peptideGlomerular filtration rateShort-term mortalityLack of improvementBUN changeDay mortalityHospital stayCreatinine levelsFirst hospitalizationFirst admissionWorse prognosisMean ageNatriuretic peptidePrognostic valueRetrospective studyThe association between fluconazole dose and MIC with mortality and persistence in candidemia
Ghanem-Zoubi N, Qasum M, Khoury J, Zorbavel D, Arnon M, Geffen Y, Paul M. The association between fluconazole dose and MIC with mortality and persistence in candidemia. European Journal Of Clinical Microbiology & Infectious Diseases 2019, 38: 1773-1780. PMID: 31197619, DOI: 10.1007/s10096-019-03611-1.Peer-Reviewed Original ResearchConceptsAUC24/MICClinical outcomesC. glabrata candidemiaComposite of mortalityExposure parametersLowest MIC valueSimilar non-significant differencesFluconazole doseFluconazole dosingPersistent candidemiaSingle centerMIC valuesClinical failureInclusion criteriaCandidemiaPatientsDay 14Non-significant differenceHigh MICsFluconazole MICsStudy periodMortalityCandida speciesMICC. glabrataRisk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy.
Ghanem-Zoubi N, Khoury J, Arnon M, Zorbavel D, Geffen Y, Paul M. Risk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy. Israel Medical Association Journal 2019, 21: 303-307. PMID: 31140219.Peer-Reviewed Original ResearchConceptsBlood stream infectionsSignificant risk factorsRisk factorsImmunosuppression therapyImmunosuppressive therapySignificant independent risk factorsRambam Health Care CampusCandida blood stream infectionEpisodes of candidemiaRetrospective cohort studyIndependent risk factorTertiary medical centerSubgroup of patientsBone marrow transplantationHealth Care CampusNon-albicans candidemiaNAC candidemiaNAC sppAdult patientsCohort studyMarrow transplantationClinical manifestationsMedical CenterCandidemiaPatients
2018
The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study
Ghanem-Zoubi N, Zorbavel D, Khoury J, Geffen Y, Qasum M, Predescu S, Paul M. The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study. European Journal Of Clinical Microbiology & Infectious Diseases 2018, 37: 2397-2404. PMID: 30284179, DOI: 10.1007/s10096-018-3389-1.Peer-Reviewed Original ResearchConceptsCLSI 2012Appropriate antifungal treatmentDefinitive treatmentOdds ratioAntifungal treatmentAntimicrobial Susceptibility Testing (EUCAST) breakpointsAppropriate definitive treatmentRetrospective observational studyAdjusted odds ratioAppropriate empirical treatmentBivariate logistic regressionCandidemia onsetCandidemia episodesEmpiric treatmentTreatment appropriatenessTertiary centerRetrospective studyCLSI breakpointsEmpirical treatmentObservational studyBreakpoint definitionPatientsResistance prevalenceMortalityLogistic regressionUnexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
Khoury J, Andrawus E, Bishop B, Azzam Z. Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence? Endocrine Regulations 2018, 52: 159-162. PMID: 31517602, DOI: 10.2478/enr-2018-0020.Peer-Reviewed Original ResearchConceptsSpontaneous bleedingDiabetes mellitusType II diabetes mellitusYear old patientExenatide treatmentAntidiabetic medicationsExact pathophysiologyOlder patientsCoagulation profileSafety profilePatient historyAbnormal plateletsBleedingSide effectsMuscular bleedingExenatideCausative relationshipEndemic diseaseMellitusPatientsTreatmentFirst reportCurrent eraMedicationsPathophysiologyIs There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? Journal Of Clinical Gastroenterology 2018, 52: 353-359. PMID: 28590324, DOI: 10.1097/mcg.0000000000000853.Peer-Reviewed Original ResearchConceptsDirect antiviral agentsAdverse eventsHepatocellular carcinomaAntiviral agentsChronic hepatitis C virus (HCV) infectionParitaprevir/ritonavir/ombitasvirHepatitis C virus infectionDe novo hepatocellular carcinomaLarge clinical trial dataSerum HCV RNAC virus infectionNovo hepatocellular carcinomaTreatment of choiceTransitional cell carcinomaAggressive hepatocellular carcinomaAggressive transitional cell carcinomaClinical trial dataDevelopment of malignancyHCV infectionHCV RNAHCV genotypesLiver diseaseCell carcinomaLaryngeal carcinomaPancreatic adenocarcinoma
2017
Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study
Khoury J, Szwarcwort M, Kra-oz Z, Saffuri M, Seh K, Yahalomi T, Braun E, Azzam Z, Paul M, Neuberger A. Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study. European Journal Of Clinical Microbiology & Infectious Diseases 2017, 37: 319-323. PMID: 29143145, DOI: 10.1007/s10096-017-3135-0.Peer-Reviewed Original ResearchConceptsRisk factorsBlood pressureDiagnostic yieldDay 2Lower diastolic blood pressureNegative PCR testIndependent risk factorProspective cohort studyProspective observational studyDiastolic blood pressureLower blood pressurePCR testInitiation of treatmentLow diagnostic yieldFirst positive testEvaluable patientsInfluenza PCROseltamivir administrationOseltamivir treatmentCohort studyMedian ageAdult inpatientsViral sheddingPositive PCRPCR positivityThe prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up
Khoury J, Arow M, Elias A, Makhoul B, Berger G, Kaplan M, Mashiach T, Ismael-Badarneh R, Aronson D, Azzam Z. The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. Journal Of Critical Care 2017, 42: 117-122. PMID: 28719839, DOI: 10.1016/j.jcrc.2017.07.009.Peer-Reviewed Original ResearchConceptsBrain natriuretic peptideLong-term mortalityBNP levelsElevated brain natriuretic peptide levelsRole of BNPBrain natriuretic peptide levelsOrgan Failure Assessment scoreNatriuretic peptide levelsNon-cardiac patientsStrong independent predictorIncidence of morbidityLow-risk groupLong-term survivalMultivariate analysis modelHospital mortalityIndex hospitalizationCritical illnessHeart failureIndependent predictorsSeptic shockNatriuretic peptideOutcome predictorsPrognostic predictorPrognostic valueMultifactorial syndrome